Date: 2014-05-08
Type of information: Establishment of a new subsidiary in the EU
Company: Lophius Biosciences (Germany)
Investors: VRD (Germany) - S-Refit (Germany)
Amount: €2 million
Funding type:
Planned used: The current investment will support the continuation into a commercial operation to further advance the clinical studies of Lophius’ flagship product T-Track® CMV for the various clinical indications and to enable the further development of the pipeline products T-Track® TB (Tuberculosis) as well as T-Track® MS (Multiple Sclerosis).With the secured financing, Dr. Robert Phelps, previously Lophius’ Director Business Operations, has been appointed as new Chief Executive Officer and the current CEO, Prof. Dr. Ralf Wagner, has been elected as Chairman of the Board, replacing Mr. Bertram Gilka-Bötzow, now one of the board’s Vice Presidents. Prof. Wagner and Dr. Phelps will work closely together to further drive the conversion of a previously research and development focused company into a commercial organization.
Others: * On May 8, 2014, Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell based research tools and diagnostic systems for functional assessment of disease-reactive T cells, announced that the company has secured a € 2,0 Million financing round. This financing was led by one of the current main investors, VRD GmbH, Heidelberg, Germany with participation of two of the existing investors one of which S-Refit AG, Regensburg.
Therapeutic area: Diagnostic - Infectious diseases - Immunological diseases - Neurodegenerative diseases
